吸毒人群中HIV/HCV核酸和抗体关系的分析

研究了高危人群中HIV/HCV核酸和抗体的关系。从新疆地区采集吸毒人群的血样,并对其进行HIV/ HCV核酸和抗体的检测。320例吸毒人员血浆样品中HCV抗体阳性为80．3％,HIV抗体阳性率为41．9％,HIV 和HCV共感染者为38．3％。HIV RNA与抗体的总符合率为98．8%,在186例HIV抗体阴性样品中可能有2例 为HIV感染的窗口期。HCV抗体和HCV RNA的阳性符合率为92．6％,HCV RNA与HCV抗体的总符合率为 90．0％,以上结果说明在HIV／HCV的高流行区进行HIV／HCV核酸检测可以发现病毒感染的窗口期,而约8% 的HCV抗体阳性样品为病毒核酸阴性,也值得进一步研究。     

外周血CD14~(high)CD16~+单核细胞在HIV/HCV重叠感染者肝损伤中的作用

目的:探讨HIV/HCV重叠感染患者外周血单核细胞亚群与肝损伤的关系。方法:观察对象为HIV/HCV重叠感染患者,分为对照组(n=11)、肝纤维化组(n=12)和肝硬化组(n=7)。运用流式细胞仪检测单核细胞及其亚群变化,瞬时弹性成像(Fibroscan)检测肝纤维化情况。比较单核细胞各亚群在不同程度肝损伤中的差异,并对HIV/HCV重叠感染患者外周血的单核细胞数与肝纤维化情况进行相关性分析。结果:HIV/HCV重叠感染患者肝硬化组与对照组比较,单核细胞CD14low CD16+和CD14high CD16+亚群显著增多(P=0.047,P=0.018)。HIV/HCV重叠感染患者肝纤维化组与对照组比较,单核细胞各亚群差异无统计学意义(P=0.84,P=0.812)。HIV/HCV重叠感染患者CD14high CD16+单核细胞与肝纤维化情况存在正性线性相关,方程成立,并且系数有统计学意义(P=0.018),方程似然比(r 2)0.45。结论:HIV/HCV重叠感染患者CD14high CD16+单核细胞增高有可能是肝损伤加重的原因之一。     

免疫渗滤法检测血液及尿液HIV抗体的应用评价

评价免疫渗滤法人类免疫缺陷病毒1+2型抗体诊断试剂盒检测人血浆和尿液样本的临床性能。采用对照试验研究,选取背景清晰的研究对象200例,采集同一研究对象的血浆和尿液样本,应用万泰生物药业公司生产的人类免疫缺陷病毒1+2型抗体诊断试剂盒作为考核试剂,法国生物梅里埃公司生产的人类免疫缺陷病毒抗体诊断试剂盒(ELISA法)作为参考试剂进行检测,考核试剂检测结果与参考试剂及研究对象背景进行比较分析。考核试剂检测血浆HIV抗体与参考试剂相比较,阳性符合率100.00%,阴性符合率100.00%,总符合率100.00%,Kappa值1.00,一致性强度为最强;考核试剂检测尿液HIV抗体与参考试剂检测结果相比较,阳性符合率68.29%,阴性符合率100.00%,总符合率87.00%,Kappa值0.72,一致性强度为高度。免疫渗滤法人类免疫缺陷病毒1+2型抗体诊断试剂盒对血浆、尿液样本检测性能优越,适合临床快速诊断。     

HIV诊断试剂的发展与使用策略

人类免疫缺陷病毒是导致艾滋病的病原,艾滋病在全球迅速传播,艾滋病防治的需要促使HIV诊断试剂不断发展。20年来HIV诊断试剂的敏感性不断提高,窗口期逐渐缩短,并且HIV诊断试剂的品种日益丰富。本文就HIV诊断试剂的品种及发展情况作一综述。     

HCV全长NS3基因表达及在抗体检测中的应用

丙型肝炎病毒(HCV)是引起非甲非乙型肝炎的主要病原因子.被HCV感染的病例中,超过50%以上会引起持续性感染、慢性肝炎,最终可能引起肝硬化和肝细胞癌[1].HCV严重威胁人类健康,但目前对丙肝患者尚缺乏有效的治疗手段,因此,严格把好血源关,提高对丙肝患者检出的灵敏度,是阻止丙肝血源传播的有效手段.     

HCV全长NS3基因表达及在抗体检测中的应用

丙型肝炎病毒 (ＨＣＶ)是引起非甲非乙型肝炎的主要病原因子。被ＨＣＶ感染的病例中 ,超过 5 0 %以上会引起持续性感染、慢性肝炎 ,最终可能引起肝硬化和肝细胞癌[1] 。ＨＣＶ严重威胁人类健康 ,但目前对丙肝患者尚缺乏有效的治疗手段 ,因此 ,严格把好血源关 ,提高对丙肝患者检出的灵敏度 ,是阻止丙肝血源传播的有效手段。丙型肝炎病毒基因组为单股正链ＲＮＡ ,核苷酸长约 9.5ｋｂ ,仅含一个开放阅读框 ,翻译成一个大的聚蛋白前体 ,由宿主细胞信号肽酶和病毒蛋白酶加工成多个成熟蛋白。其中非结构蛋白ＮＳ3分子量为 70ｋＤ ,有丝氨酸蛋白酶…     

Dot-ELISA法检测血液及唾液HIV抗体的应用评价

评价人类免疫缺陷病毒1+2型抗体检测试剂盒(Dot-ELISA法)检测血清和唾液样本的临床性能。采用对照试验研究,选取背景清晰的研究对象200例,采集同一研究对象的血清和唾液样本,应用万泰生物药业公司生产的人类免疫缺陷病毒1+2型抗体检测试剂盒作为考核试剂,法国生物梅里埃公司生产的人类免疫缺陷病毒抗体诊断试剂盒(ELISA法)作为参考试剂,考核试剂检测结果与参考试剂及研究对象背景进行比较分析。考核试剂检测血清HIV抗体与参考试剂相比较,阳性符合率100%,阴性符合率100%,总符合率100%,Kappa值1.00,一致性为最强;考核试剂检测唾液HIV抗体与参考试剂检测结果相比较,阳性符合率98.78%,阴性符合率100%,总符合率99.50%,Kappa值0.99,一致性为最强。Dot-ELISA法人类免疫缺陷病毒1+2型抗体检测试剂盒对血清及唾液样本检测性能优越,适合HIV抗体快速筛查。     

2014—2018年平顶山市湛河区艾滋病自愿咨询检测者HIV抗体调查分析

目的了解平顶山市湛河区艾滋病自愿咨询检测(voluntary counseling and testing, VCT)的人类免疫缺陷病毒(human immunodeficiency virus, HIV)抗体情况,为全区科学防治艾滋病工作提供理论依据。方法通过湛河区疾病预防控制中心2014—2018年3 205例VCT HIV抗体分析,研究同期报告的艾滋病病例的感染状况和人群分布特征。结果 2014—2018年湛河区疾病预防控制中心对3 205人次VCT并进行HIV抗体筛查,阳性21例,阳性率0.66%。VCT HIV抗体阳性和阳性率最高的年份是2016和2017年,各年份间无明显趋势变化,各年份差异无统计学意义;男女性别比为1.60∶1,男性VCT HIV抗体阳性和阳性率高于女性,性别差异无统计学意义;年龄分布以青壮年为主,年龄集中在>20～40岁组,占64.93%;文化程度分布,以初中及以下人群的构成比最高;婚姻状况分布发现,已婚VCT HIV抗体阳性和阳性率最多;不同高危人群HIV抗体检测,男男性行为抗体阳性率是异性性行为的23.24倍。结论疾病预防控制中心VCT是HIV阳性发现的主要部门,需进一步重视和扩大VCT门诊;加强人们艾滋病预防知识的普及工作,特别针对外来务工人员、高危行为者中男男性行为者的健康教育和行为干预;同时对婚检人群抗体阳性的出现引起足够的重视。     

HCV感染者抗HCV抗体产生的不均匀性与B细胞优势克隆

本文采用抗原捕捉ＥＬＩＳＡ方法检测了ＨＣＶ感染者血清中抗－ＨＣＶＩｇＧ抗体轻链Κ和λ的比值,发现所检测的抗ＨＣＶ－ＮＳ４、抗ＨＣＶ－ＣＰ１和抗ＨＣＶ－ＣＰ２抗体轻链的表达呈现明显的偏斜,６５例抗ＨＣＶ阳性者中６３例（占９６．９％）,至少一种抗ＨＣＶ抗体К／λ偏离了正常１∶１的比值,尤以λ链较多,分别占６５．６％、８９．９％和７０．２％,但任何一个ＨＣＶ感染者血清抗－ＨＣＶ抗体既可能是Κ链占优势,也     

不同人类免疫缺陷病毒感染途径群体中戊型肝炎病毒的流行情况

本研究旨在了解不同人类免疫缺陷病毒(human immunodeficiency virus,HIV)感染途径群体中戊型肝炎病毒(hepatitis E virus,HEV)抗体情况,探讨HEV疫苗接种的必要性。采集HIV感染者的血清或血浆,利用酶联免疫吸附试验(enzyme-linked immunosorbent assay,ELISA)检测HEV IgG抗体、IgM抗体及抗原,荧光定量聚合酶链反应(polymerase chain reaction,PCR)检测HEV核酸,Roche高纯化HIV-1核酸定量检测试剂盒(PCR荧光法)检测HIV感染者的HIV载量。比较分析不同HIV感染途径群体中HEV流行率的差别。结果显示,HIV感染者中HEV IgG抗体的阳性率为37.4%,静脉吸毒、成分献血和传播途径不明HIV感染群体的HEV IgG抗体阳性率分别为49.3%、39.5%和30.4%。HEV核酸荧光PCR检测结果均为阴性。3种HIV感染群体之间HEV IgG抗体阳性率差异无统计学意义(χ~2=2.978,P0.05)。HEV IgG阳性与阴性感染者之间HIV载量差异无统计学意义(P0.05)。结果提示,为保护HIV感染者免受HEV感染,应考虑接种HEV疫苗。     

Modeling the HIV/AIDS Epidemic Among Injecting Drug Users and Sex Workers in Kunming, China

This paper presents a mathematical model of the HIV/AIDS epidemic in Kunming,the provincial capital of Yunnan, China. The population is divided into several groups, with individuals possibly changing group. Two transmission routes of HIV are considered: needle sharing betweeninjecting drug users (IDUs) and commercial sex between female sex worker(FSWs) and clients. The model includes male IDUs who are also clients and female IDUs who are also FSWs. Groups are split in two—risky and safe—according to condom use and needle sharing. A system of partialdifferential equations is derived to describe the spread of the disease. For the simulation, parameters are chosen to fit as much as possibledata publicly available for Kunming. Some mathematical properties of the model—in particular the epidemic threshold R ⁰ which determines the goal of public health interventions—are also presented. Though the model couples two transmission routes of HIV, the approximation , with closed formulas for and , appears to be quite good. The critical levels of condom use and clean needle use necessary to stop both the sexual transmission and the transmission among IDUs can therefore be determined independently.     

The Molecular Epidemiological Study of HCV Subtypes among Intravenous Drug Users and Non-Injection Drug Users in China

BackgroundMore than half of intravenous drug users (IDUs) in China suffer from the Hepatitis C virus (HCV). The virus is also more prevalent in non-injection drug users (NIDUs) than in the general population. However, not much is known about HCV subtype distribution in these populations.MethodsOur research team conducted a cross-sectional study in four provinces in China. We sampled 825 IDUs and 244 NIDUs (1162 total), genotyped each DU’s virus, and performed a phylogenetic analysis to differentiate HCV subtypes.ResultsNucleic acid testing (NAT) determined that 82% percent (952/1162) of samples were HCV positive; we subtyped 90% (859/952) of these. We found multiple HCV subtypes: 3b (249, 29.0%), 3a (225, 26.2%), 6a (156, 18.2%), 1b (137, 15.9%), 6n (50, 5.9%), 1a (27, 3.1%), and 2a (15, 1.7%). An analysis of subtype distributions adjusted for province found statistically significant differences between HCV subtypes in IDUs and NIDUs.DiscussionHCV subtypes 3b, 3a, 6a, and 1b were the most common in our study, together accounting for 89% of infections. The subtype distribution differences we found between IDUs and NIDUs suggested that sharing syringes was not the most likely pathway for HCV transmission in NIDUs. However, further studies are needed to elucidate how NIDUs were infected.     

Cost Effectiveness of Screening Strategies for Early Identification of HIV and HCV Infection in Injection Drug Users

Objective

To estimate the cost, effectiveness, and cost effectiveness of HIV and HCV screening of injection drug users (IDUs) in opioid replacement therapy (ORT).

Design

Dynamic compartmental model of HIV and HCV in a population of IDUs and non-IDUs for a representative U.S. urban center with 2.5 million adults (age 15–59).

Methods

We considered strategies of screening individuals in ORT for HIV, HCV, or both infections by antibody or antibody and viral RNA testing. We evaluated one-time and repeat screening at intervals from annually to once every 3 months. We calculated the number of HIV and HCV infections, quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs).

Results

Adding HIV and HCV viral RNA testing to antibody testing averts 14.8–30.3 HIV and 3.7–7.7 HCV infections in a screened population of 26,100 IDUs entering ORT over 20 years, depending on screening frequency. Screening for HIV antibodies every 6 months costs $30,700/QALY gained. Screening for HIV antibodies and viral RNA every 6 months has an ICER of $65,900/QALY gained. Strategies including HCV testing have ICERs exceeding $100,000/QALY gained unless awareness of HCV-infection status results in a substantial reduction in needle-sharing behavior.

Discussion

Although annual screening for antibodies to HIV and HCV is modestly cost effective compared to no screening, more frequent screening for HIV provides additional benefit at less cost. Screening individuals in ORT every 3–6 months for HIV infection using both antibody and viral RNA technologies and initiating ART for acute HIV infection appears cost effective.     

艾滋病毒核酸探针的制备

 采用PXY104(含化学合成的HIV-env26肽基因4重串联体结构)为材料。温和裂解法提取质粒DNA,制备电泳纯化,Hind Ⅲ和EcoR Ⅰ酶解,低融点琼脂糖凝胶电泳回收HIV-DNA片段作为核酸探针;用[α-~(32)P]dATP通过缺口移位法标记,比放射性为4.05—6.69×10~7cpm/μgDNA通过分子杂交能测出lPg的靶DNA,初步试验结果表明,在本文试验条件下,可用该探针检测与之互补的核酸分子。     

Nucleic Acid Homologies Among Species of Saccharomyces

Evolutionary divergence among species of the yeast genus Saccharomyces was estimated from measurements of deoxyribonucleic acid (DNA)/DNA and ribosomal ribonucleic acid (RNA)/DNA homology. Much diversity was found in the DNA base sequences with several species showing little or no homology to the three reference species, S. cerevisiae, S. lactis, and S. fragilis. These three reference species also showed little or no homology to each other. On the other hand the diversity among ribosomal RNA base sequences was small since most species showed a high degree of homology to the reference species. The arrangement of species based on ribosomal RNA homologies agrees in most cases with current taxonomic groupings. A yeast hybrid (S. fragilis x S. lactis) was shown to contain two nonhomologous genomes. A minimum genome size of 9.2 x 10(9) daltons for S. cerevisiae was calculated from the rate of DNA renaturation.     

血源性乙型肝炎病毒、丙型肝炎病毒和艾滋病病毒核酸筛查系统的建立与应用

目的：建立同时实现乙型肝炎病毒（hepatitisBvirus,HBV）、丙型肝炎病毒（hepatitisCvirus,HCV）、艾滋病病毒（humanImmunodeficiencyVirus,HIV）检测的多重核酸筛查系统。方法：以HBV、HCV、HIV的保守序列为模板设计特异性引物和探针,通过核酸自动提取系统结合一步法RT-PCR技术平台,优化相关反应体系和条件,建立多重多色实时荧光PCR检测血源性传播病毒的核酸筛查系统。将该系统用于101387例血浆样本的筛查。结果：本研究建立的核酸筛查系统特异性好,HBV灵敏度可以达到20IU／ml,HCV灵敏度可以达到100IU／ml,HIV灵敏度可以达到50IU／mL。结论：本研究建立的核酸筛查系统具有高度自动化、高灵敏度、低成本等特点,适合我国血站系统推广使用。     

血源性乙型肝炎病毒、丙型肝炎病毒和艾滋病病毒核酸筛查系统的 建立与应用

摘要目的：建立同时实现乙型肝炎病毒(hepatitis B virus,HBV)、丙型肝炎病毒(hepatitis C virus,HCV)、艾滋病病毒(human Immunodeficiency Virus,HIV)检测的多重核酸筛查系统。方法：以HBV、HCV、HIV 的保守序列为模板设计特异性引物和探针,通 过核酸自动提取系统结合一步法RT-PCR技术平台,优化相关反应体系和条件,建立多重多色实时荧光PCR检测血源性传播病 毒的核酸筛查系统。将该系统用于101387 例血浆样本的筛查。结果：本研究建立的核酸筛查系统特异性好,HBV灵敏度可以达到 20IU/ml,HCV 灵敏度可以达到100IU/ml,HIV 灵敏度可以达到50IU/mL。结论：本研究建立的核酸筛查系统具有高度自动化、高 灵敏度、低成本等特点,适合我国血站系统推广使用。     

电化学发光分析法在核酸杂交检测和药物筛选中应用

该文简要介绍了电化学发光（ECL）核酸分析法的基本原理,评述了ECL分析法在核酸杂交检测和药物筛选中应用的研究进展。